Nintedanib Instructions: Learn more about the instructions for use of this drug, including indications, dosage, contraindications, and side effects.

Nintedanib (Nintedanib) is an oral tyrosine kinase inhibitor mainly used to treat certain types of lung diseases, especially diseases related to pulmonary fibrosis. It inhibits the action of multiple receptor tyrosine kinases and interferes with cell proliferation, migration and differentiation, thereby slowing down the progression of pulmonary fibrosis. Nintedanib is commonly used clinically to treat idiopathic pulmonary fibrosis (IPF) and some diseases related to pulmonary fibrosis, such as systemic sclerosis-related interstitial lung disease (SSc-ILD).

1. Indications

The main indication for nintedanib is the treatment of idiopathic pulmonary fibrosis (IPF), which is a chronic disease caused by interstitial changes in the lungs, which is accompanied by the gradual loss of lung function and may eventually lead to respiratory failure. Nintedanib can slow the progression of the disease and improve patients' quality of life. In addition, nintedanib is also approved for the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD), an interstitial lung disease caused by systemic sclerosis that leads to damage to lung tissue and the gradual formation of fibrosis. By inhibiting biological pathways associated with fibrosis, nintedanib can effectively slow the progression of the disease.

2. Dosage and usage

Nintedanib is usually administered as an oral capsule, with the recommended regular dose being 150 mg twice daily after meals. Based on the patient's tolerance and treatment response, the doctor can adjust the dosage appropriately. For patients who cannot tolerate the 150mg dose, a dose reduction to 100mg or 75mg may be considered. During the treatment process, patients need to undergo liver function, kidney function and other related tests regularly to ensure the safety of drug use. Coadministration of nintedanib with strong CYP3A4 inhibitors is not recommended as this may increase plasma concentrations of the drug and increase the risk of side effects.

3. Contraindications

Contraindications to nintedanib mainly include patients who are allergic to components of the drug. Patients should avoid use if they have ever had an allergic reaction to nintedanib or any of its ingredients. Additionally, patients with severe hepatic impairment (such as those with cirrhosis) should not use nintedanib because the drug is metabolized by the liver, which may result in accumulation of the drug in patients with impaired hepatic function and increase the risk of side effects. Pregnant and breastfeeding women should also not use nintedanib unless their doctor determines that the benefits outweigh the risks and that use needs to be carefully monitored in special circumstances.

4. Side Effects

Common side effects of nintedanib include gastrointestinal upset, such as nausea, vomiting, diarrhea, and loss of appetite. To reduce gastrointestinal discomfort, patients should take medication after meals and adjust their diet according to doctor's recommendations. In addition, nintedanib may cause abnormal liver function, and patients should have their liver function monitored regularly during treatment. If abnormalities in liver function indicators occur, dose adjustment or temporary discontinuation may be required. Other more common side effects include fatigue, headache, and weight loss.

More serious but rare side effects include thromboembolic events such as deep vein thrombosis, pulmonary embolism, etc., especially in patients with underlying medical conditions or a history of venous thrombosis. Nintedanib may also cause hypertension, so patients need to monitor their blood pressure during treatment. If blood pressure rises too quickly, medications may need to be adjusted or antihypertensive medications may need to be used simultaneously.

5. Special groups and precautions

When using nintedanib, patients with hepatic and renal insufficiency need to pay special attention. Patients with hepatic insufficiency need to adjust the dose or avoid use. Drugs may be metabolized differently in elderly patients and their use requires careful evaluation of the indications and risks. In addition, patients should avoid exposure to drugs that may interact with the drug while taking nintedanib, especially CYP3A4 inhibitors or inducers. Nintedanib may also cause rashes and hair loss. Patients should check their skin status regularly during treatment and report to their doctor in a timely manner.

In conclusion, nintedanib, a drug used to treat pulmonary fibrosis, has a significant effect on slowing the progression of idiopathic pulmonary fibrosis and systemic sclerosis-related interstitial lung disease. However, patients need to follow the doctor's instructions and undergo regular examinations when using this drug to ensure its efficacy and safety and avoid the occurrence of adverse reactions.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib